PHILADELPHIA, Aug. 6, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its financial results for the three months ended June 30, 2010. The net loss (including non-cash expenses) for the 2nd fiscal quarter was approximately $3,676,000 or $0.03 per share compared to a loss of approximately $3,870,000 or $0.04 per share for the same period in 2009. In comparison of fiscal quarters, year 2010 had decreased Research and Development costs and General and Administrative costs were also reduced due to non-recurring financing expense. For the six months ended June 30, 2010, the net loss was approximately $7,720,000 or $0.06 per share as compared to a loss of $6,957,000 or $0.08 per share for the same period in 2009.